期刊文献+

210例髓母细胞瘤临床病理研究及预后因素分析 被引量:4

Clinicopathological and Prognostic Factor Analysis in 210 Cases of Medulloblastoma
暂未订购
导出
摘要 目的 :分析髓母细胞瘤 (MB)的临床病理特点及影响预后的因素。方法 :对 33年间病理证实的 2 10例 MB进行组织学及免疫组织化学观察。采用 L og- rank检验进行预后分析。结果 :MB病人术后 1年、3年及 5年生存率分别为 34.6 5 %、13.77%和 10 .71% ,平均生存 2 2个月。与病人生存期延长的有关因素为病人年龄≥ 18岁 (P=0 .0 44 4)、促纤维增生型 MB(P=0 .0 317) PCNA标记指数低 (P=0 .0 2 2 7)、肿瘤无灶状坏死 (P=0 .0 0 0 2 )及术后接受放射治疗 (P=0 .0 0 0 1)。性别、术前病程长短、肿瘤大小、部位及分化程度与病人预后无明显关系。结论 :年龄、组织类型、细胞增殖活性、肿瘤灶状坏死及术后放疗是与 MB病人预后有关的重要因素。 Objective:To study the clinicopathological features and evaluate the effect of various factors on survival in medulloblastoma.Methods:210 cases of cerebellar medulloblastoma were observed with histological and immunohistochemical methods.Difference in survival among groups was analyzed by the log rank test.Results:The median time of survival after operation was 22 months.The overall 1,3,5 year survival rate were 34.63%,13.77% and 10.71% respectively.Significant factors in predicting a longer postoperative survival were age>18 year (P=0.0444),desmoplastic type (P=0.0317),lower proliferative index (P=0.0227),no focal necrosis in tumor (P=0.0002),and receiving radiation Therapy after operation (P=0.0001).Other factors such as sex,size, location and differentiation of tumor had no effect on prognosis.Conclusion:Age,histological type,proliferative index,focal necrosis and post operative craniospinal irradiation in medulloblastoma are significant prognostic factors.
出处 《中国肿瘤临床与康复》 1998年第4期4-6,共3页 Chinese Journal of Clinical Oncology and Rehabilitation
关键词 髓母细胞瘤 病理学 增殖细胞核抗原 预后 Medulloblastoma Prognosis Pathology
  • 相关文献

参考文献1

  • 1Felice Giangaspero,Pasquale Chieco,Claudio Ceccarelli,Gina Lisignoli,Roberto Pozzuoli,Marcello Gambacorta,Giorgio Rossi,Peter C. Burger. “Desmoplastic” versus “classic” medulloblastoma: Comparison of DNA content, histopathology and differentiation[J] 1991,Virchows Archiv A Pathological Anatomy and Histopathology(3):207~214

同被引文献21

  • 1Sardinas N, Marcos R, Pestana EM, et al.Tumors of the posterior fossa in children. Rev Neurol,1999,16(28):1153-1158.
  • 2Taylor RE, Bailey CC, Robinson K J, et aL Outcome for patients with metastatic (M2.3 ) medulloblastoma treated with SIOP/ UKCCSG PNET-3 chemotherapy [ J] .Eur J Cancer,2005,41 (5) : 727-734.DOI : 10.1016/j.ejea.2004.12.017.
  • 3Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted cranio- spinal radiotherapy followed by high-dose chemotherapy and stem- cell rescue in children with newly diagnosed medulloblastoma (StJude Medulloblastoma-96) :long-terra results from a prospective, multicentre trial [ J ]. Lancet Oncol, 2006,7 ( 10 ) : 813-820. DOI : 10.1016/S1470-2045 (06) 70867-1.
  • 4Tarbell N J, Friedman H, Polkinghom WR, et al. High-risk medul- loblastoma: a pediatric oncology group randomized trim of chemo- therapy before or after radiation therapy (POG 9031 ) [J] .J Clin Oncol, 2013,31 ( 23 ) : 2936-2941. DOI : 10. 1200/JCO. 2012.43. 9984.
  • 5Morris EB, Gajjar A, Okuma JO, et al. Survival and late mortality in long-term survivors of pediatric CNS tumors [ J ]. J Clin Oncol, 2007,25(12) : 1532-1538.DOI: 10.1200/JCO.2006.09.8194.
  • 6Packer RJ, Gajjar A, Vezina G, et al. Phase III study of eraniospi- hal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma [ J]. J Clin Oncol, 2006, 24(25) :4202-4208.DOI : 10.1200/JCO.2006.06,4980.
  • 7Zehzer PM,Boyett JM, Finlay JL, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medullo- blastoma in children: conclusions from the Children's Cancer Group 921 randomized phase IU study [ J] .5 Clin Oncol, 1999,17 (3) :832-845.
  • 8Landberg TG, Lindgren ML, Cavallin-Stahl EK, et al. Improve- ments in the radiotherapy of medulloblastoma, 1946-1975 [J]. Cancer, 1980, 45 ( 4 ) : 670-678. DOI: 10. 1002/1097-0142 (19800215) 45:4<670: : AID-CNCR2820450409 > 3. O.CO : 2-K.
  • 9Laughton SJ, Merchant TE, Sklar CA, et al. Endocrine outcomes for children with embryonal brain tumors after risk-adapted craniospi- hal and conformal primary-site irradiation and high-dose chemo- therapy with stem-cell rescue on the SJMB-96 trial [ J] .J Clin On- col,2008,26(7) : 1112-1118.DOI : 10.1200/JCO.2008.13.5293.
  • 10Oyharcabal-Bourden V, Kalifa C, Gentet JC, et al. Standard-risk medulloblastoma treated by adjuvant chemotherapy followed by re- duced-dose craniospinal radiation therapy : a French Society of Ped- iatric Oncology Study [J]. J Clin Oncol, 2005, 23 (21) :4726- 4734.DOI : 10.1200/JCO.2005.00.760.

引证文献4

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部